Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announces that it has granted options to its officers, employees, consultants and members of the board of directors. A total of 2,275,000 options have been granted effective at the close of business on September 1st, 2011. The options are exercisable at a price of $0.52 per share until August 31st, 2016. The options shall vest in accordance with the company?s stock option plan.
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Cognitest, a blood test for the diagnosis of Alzheimer’s disease. biOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”
On Behalf of the Board of Directors
Chairman & CEO